VOXZOGO (vosoritide)
Achondroplasia
Approved/MarketedActive (Lifecycle management)
Key Facts
Indication
Achondroplasia
Phase
Approved/Marketed
Status
Active (Lifecycle management)
Company
About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a mission-driven, revenue-generating biotech leader with a 25+ year track record of translating genetic insights into transformative medicines for rare diseases. The company's strategy centers on pursuing 'category-defining' therapies in areas of well-understood biology, leveraging core platforms in enzyme replacement therapy (ERT) and gene therapy. This approach has yielded a commercial portfolio generating significant revenue and a promising clinical pipeline, underpinned by global commercial and manufacturing infrastructure. BioMarin's financial strength and operational maturity support its ambition to sustainably deliver breakthrough science to patients worldwide.
View full company profileTherapeutic Areas
Other Achondroplasia Drugs
| Drug | Company | Phase |
|---|---|---|
| Navepegritide (TransCon CNP) | VISEN Pharmaceuticals | Phase 2 |
| Infigratinib | BridgeBio Pharma | Phase 3 |